Literature DB >> 12906815

c-Abl regulation: a tail of two lipids.

Richard A Van Etten1.   

Abstract

c-Abl is a non-receptor tyrosine kinase whose activity is tightly controlled in vivo through unknown mechanisms. Recent studies suggest that c-Abl may be regulated in different cellular contexts by distinct lipids.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12906815     DOI： 10.1016/s0960-9822(03)00528-1

Source DB:  PubMed          Journal:  Curr Biol        ISSN： 0960-9822            Impact factor:   10.834


  12 in total

1.  Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts.

Authors:  Y Lynn Wang; Joong Won Lee; Ethel Cesarman; David K Jin; Balazs Csernus
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

2.  TRPM7, a novel regulator of actomyosin contractility and cell adhesion.

Authors:  Kristopher Clark; Michiel Langeslag; Bart van Leeuwen; Leonie Ran; Alexey G Ryazanov; Carl G Figdor; Wouter H Moolenaar; Kees Jalink; Frank N van Leeuwen
Journal:  EMBO J       Date:  2006-01-12       Impact factor: 11.598

3.  Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton.

Authors:  Sajjad Hossain; Patrycja M Dubielecka; Aleksander F Sikorski; Raymond B Birge; Leszek Kotula
Journal:  Genes Cancer       Date:  2012-05

4.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

5.  Altered subcellular distribution of c-Abl in Alzheimer's disease.

Authors:  Zheng Jing; John Caltagarone; Robert Bowser
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 6.  Aberrant cytokine signaling in leukemia.

Authors:  R A Van Etten
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

7.  Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.

Authors:  Martin Preyer; Paolo Vigneri; Jean Y J Wang
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

Review 8.  Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.

Authors:  Guilherme A P de Oliveira; Luciana P Rangel; Danielly C Costa; Jerson L Silva
Journal:  Front Oncol       Date:  2015-04-29       Impact factor: 6.244

Review 9.  The alpha-kinase family: an exceptional branch on the protein kinase tree.

Authors:  Jeroen Middelbeek; Kristopher Clark; Hanka Venselaar; Martijn A Huynen; Frank N van Leeuwen
Journal:  Cell Mol Life Sci       Date:  2009-12-12       Impact factor: 9.261

Review 10.  The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Authors:  Taira Maekawa; Eishi Ashihara; Shinya Kimura
Journal:  Int J Clin Oncol       Date:  2007-10-22       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.